Institutions / Privium Fund Management B.V. / Activity
Activity — Privium Fund Management B.V.
69 moves.
| Date | Action | Company | Value | Shares Δ | Position after | Impact |
|---|---|---|---|---|---|---|
| Q2 2026 as of | New | Opendoor Technologies Inc. Common stock | $18.21M | +3.9M | 3,940,904 3.35% of portfolio | medium |
| Q2 2026 as of | Exit | Coinbase Global, Inc. Common stock | $-17.87M | -79K -100.00% | 0 | medium |
| Q2 2026 as of | Exit | Sea Ltd Common stock | $-17.60M | -138K -100.00% | 0 | medium |
| Q2 2026 as of | New | Cerebras Systems Inc. Common stock | $13.37M | +61K | 60,500 2.46% of portfolio | medium |
| Q2 2026 as of | Trim | Arrowhead Pharmaceuticals, Inc. Common stock | $-13.37M | -164K -41.18% | 234,222 3.51% of portfolio | medium |
| Q2 2026 as of | New | SPCX Space Exploration Technologies Corp Common Stock | $6.83M | +40K | 40,000 1.26% of portfolio | medium |
| Q2 2026 as of | Add | Ionis Pharmaceuticals Inc Common stock | $6.27M | +79K +32.85% | 319,924 4.66% of portfolio | medium |
| Q2 2026 as of | Trim | L8681T102 Common stock | $-5.97M | -13K -19.12% | 55,000 4.64% of portfolio | medium |
| Q2 2026 as of | New | Denali Therapeutics Inc. Common stock | $5.91M | +230K | 229,857 1.09% of portfolio | medium |
| Q2 2026 as of | Trim | Biogen Inc. Common stock | $-5.42M | -25K -34.13% | 48,400 1.92% of portfolio | medium |
| Q2 2026 as of | Trim | 82509L107 Common stock | $-4.57M | -40K -9.76% | 370,000 7.76% of portfolio | low |
| Q2 2026 as of | Add | Amazon.com Inc Common stock | $4.53M | +19K +15.70% | 140,000 6.13% of portfolio | low |
| Q2 2026 as of | New | BioMarin Pharmaceutical Inc Common stock | $4.29M | +75K | 75,000 0.79% of portfolio | low |
| Q2 2026 as of | Trim | Axsome Therapeutics, Inc. Common stock | $-4.14M | -17K -29.77% | 39,944 1.80% of portfolio | low |
| Q2 2026 as of | Trim | N90064101 Common stock | $-4.05M | -88K -21.13% | 328,322 2.78% of portfolio | low |
| Q2 2026 as of | Exit | Merck & Co., Inc. Common stock | $-3.85M | -37K -100.00% | 0 | low |
| Q2 2026 as of | New | Alnylam Pharmaceuticals Inc Common stock | $3.42M | +11K | 11,372 0.63% of portfolio | low |
| Q2 2026 as of | Exit | enGene Therapeutics Inc. Common stock | $-3.18M | -352K -100.00% | 0 | low |
| Q2 2026 as of | Add | Q4982L109 Common stock | $2.75M | +60K +21.48% | 340,150 2.86% of portfolio | low |
| Q2 2026 as of | Add | Arcutis Biotherapeutics, Inc. Common stock | $2.45M | +93K +30.52% | 399,367 1.92% of portfolio | low |
| Q2 2026 as of | Exit | Stoke Therapeutics, Inc. Common stock | $-1.75M | -55K -100.00% | 0 | low |
| Q2 2026 as of | Add | Sarepta Therapeutics, Inc. Common stock | $1.68M | +94K +217.44% | 136,500 0.45% of portfolio | low |
| Q2 2026 as of | Trim | 4D Molecular Therapeutics, Inc. Common stock | $-1.59M | -120K -57.09% | 90,110 0.22% of portfolio | low |
| Q2 2026 as of | New | N5505D105 Common stock | $1.50M | +98K | 98,221 0.27% of portfolio | low |
| Q2 2026 as of | Exit | Slb LIMITED/NV Common stock | $-1.49M | -39K -100.00% | 0 | low |
| Q2 2026 as of | Add | Lemonade, Inc. Common stock | $1.43M | +22K +8.86% | 270,259 3.23% of portfolio | low |
| Q2 2026 as of | Add | Hims & Hers Health, Inc. Common stock | $1.39M | +40K +100.00% | 80,000 0.51% of portfolio | low |
| Q2 2026 as of | Trim | Moderna, Inc. Common stock | $-1.37M | -20K -39.52% | 29,994 0.39% of portfolio | low |
| Q2 2026 as of | New | Zoetis Inc. Common stock | $1.24M | +17K | 17,322 0.23% of portfolio | low |
| Q2 2026 as of | Add | Advanced Micro Devices Inc Common stock | $1.16M | +2K +3.33% | 62,000 6.62% of portfolio | low |
| Q2 2026 as of | Exit | 92859G608 Common stock | $-1.12M | -205K -100.00% | 0 | low |
| Q2 2026 as of | New | LEGN Legend Biotech Corp ADR | $1.02M | +35K | 35,400 0.19% of portfolio | low |
| Q2 2026 as of | Exit | Pfizer Inc Common stock | $-940.0K | -38K -100.00% | 0 | low |
| Q2 2026 as of | Trim | ABEV Ambev S.A. ADR | $-819.6K | -261K -24.55% | 802,167 0.46% of portfolio | low |
| Q2 2026 as of | New | 11777Q209 Common stock | $729.6K | +195K | 195,083 0.13% of portfolio | low |
| Q2 2026 as of | New | TotalEnergies SE Common stock | $729.5K | +11K | 10,723 0.13% of portfolio | low |
| Q2 2026 as of | Exit | Seabridge Gold Inc. Common stock | $-702.9K | -24K -100.00% | 0 | low |
| Q2 2026 as of | New | Molina Healthcare Inc Common stock | $681.3K | +3K | 2,979 0.13% of portfolio | low |
| Q2 2026 as of | Trim | Ultragenyx Pharmaceutical Inc. Common stock | $-624.5K | -19K -5.23% | 338,800 2.08% of portfolio | low |
| Q2 2026 as of | New | G6683N103 Common stock | $587.8K | +44K | 44,000 0.11% of portfolio | low |
| Q2 2026 as of | New | Lululemon Athletica Inc Common stock | $578.1K | +5K | 5,063 0.11% of portfolio | low |
| Q2 2026 as of | New | 811927102 Common stock | $425.0K | +17K | 16,512 0.08% of portfolio | low |
| Q2 2026 as of | Trim | Krystal Biotech, Inc. Common stock | $-371.7K | -1K -8.22% | 11,170 0.76% of portfolio | low |
| Q2 2026 as of | Exit | Valaris Ltd Common stock | $-318.3K | -6K -100.00% | 0 | low |
| Q2 2026 as of | Exit | Noble Corp plc Common stock | $-306.4K | -11K -100.00% | 0 | low |
| Q2 2026 as of | Add | N71542109 Common stock | $301.8K | +162K +3.03% | 5,520,024 1.89% of portfolio | low |
| Q2 2026 as of | Trim | BNTX BioNTech SE ADR | $-297.8K | -3K -9.61% | 30,100 0.51% of portfolio | low |
| Q2 2026 as of | Exit | 85208P303 Common stock | $-296.8K | -5K -100.00% | 0 | low |
| Q2 2026 as of | New | ENGN enGene Therapeutics Inc. Common Stock | $294.1K | +170K | 170,000 0.05% of portfolio | low |
| Q2 2026 as of | Add | Y95308105 Common stock | $278.9K | +48K +24.87% | 241,010 0.26% of portfolio | low |